AJOONI
Ajooni Biotech financials
- Market cap
- ₹60 Cr
- Sector
- Fast Moving Consumer Goods
What Ajooni Biotech Limited does
Ajooni Biotech makes vegetarian (no animal by-product) compounded cattle feed, cattle feed chips, camel feed, cotton oil cake and mustard oil cake, plus a range of feed supplements (mineral mixtures, tonics, digestive powders, multivitamins) at its GMP-certified plant in Khanna, Punjab. It sells mainly to large institutional dairy and milk-processing clients such as Mother Dairy, Paras Dairy, Saahaj Dairy, Banas Dairy and National Dairy Services, while also building out a direct dealer/distributor network to reach farmers, and exports to Nepal, Bangladesh and Sri Lanka.
Segments
- Feed & Others
- Supplements
- Manufacturing units
- 3
- PURE VEG. animal feed installed capacity
- 57,000 MTPA (further 70,000 MTPA expansion in process)
- Dry powder supplement capacity
- 3,000 MTPA
- Liquid supplement capacity
- 55 lakh litres
- Warehouse size
- 40,000 sq ft
- Dealer/distributor network
- 150+ (FY25)
Quarterly results
Q1 FY27: revenue up 103.0%, net profit down 44.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 34 | 29 | 31 | 32 +23% | 59 +73% | 61 +107% | 63 +103% |
| EBITDA | 1 | 1 | 1 | 1 | 2 +95% | 3 +226% | 1 +0% | 2 +135% |
| Net profit | 1 | 1 | 2 | 1 | 1 +50% | 2 +126% | 1 −38% | 0 −45% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −32.6% 1Y
1Y: ₹5.15 on 10 Sept 2025 → ₹3.47. High ₹5.85 (18 Sept 2025), low ₹3.44 (8 Sept 2026).
Financials, as filed
Revenue grew 50.9% a year over 2 years, FY24 to FY26. Operating margin widened to 3.4%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹80 Cr | ₹115 Cr | ₹182 Cr |
| Operating profit | ₹2 Cr | ₹4 Cr | ₹6 Cr |
| Operating margin | 2.8% | 3.2% | 3.4% |
| Interest | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Depreciation | ₹1 Cr | ₹1 Cr | ₹2 Cr |
| Net profit | ₹2 Cr | ₹3 Cr | ₹4 Cr |
| Net margin | 2.7% | 2.9% | 2.4% |
| Cash from operations | ₹23 Cr | ₹-18 Cr | ₹-6 Cr |
| Free cash flow | ₹17 Cr | ₹-19 Cr | ₹-23 Cr |
| ROCE | 8.0% | 7.0% | 6.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹10 Cr | ₹18 Cr | ₹18 Cr | ₹34 Cr | ₹34 Cr |
| Reserves | ₹6 Cr | ₹6 Cr | ₹24 Cr | ₹25 Cr | ₹55 Cr | ₹57 Cr |
| Borrowings | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹2 Cr | ₹9 Cr | ₹18 Cr |
| Other liabilities | ₹6 Cr | ₹7 Cr | ₹12 Cr | ₹3 Cr | ₹5 Cr | ₹11 Cr |
| Total liabilities | ₹28 Cr | ₹29 Cr | ₹59 Cr | ₹48 Cr | ₹104 Cr | ₹120 Cr |
| Fixed assets | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹10 Cr | ₹11 Cr | ₹26 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹11 Cr | ₹0 Cr |
| Investments | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
| Other assets | ₹22 Cr | ₹22 Cr | ₹48 Cr | ₹34 Cr | ₹78 Cr | ₹92 Cr |
| Total assets | ₹28 Cr | ₹29 Cr | ₹59 Cr | ₹48 Cr | ₹104 Cr | ₹120 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, promoters added +3.64 pp while the public trimmed −3.64 pp. The shareholder count shrank 6% to 60,170.
- Promoters
- 30.5%
- Public
- 69.5%
Since Sep 2025
- Promoters +3.64 pp
- Public −3.64 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Over this window promoters went from 26.4% to 30.5% — +4.1 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 26.4%, Public 73.6%.Mar '24: Promoters 26.4%, Public 73.6%.Jun '24: Promoters 26.9%, Public 73.1%.Sep '24: Promoters 26.9%, FIIs 0.3%, Public 72.8%.Dec '24: Promoters 26.9%, FIIs 0.2%, Public 72.9%.Mar '25: Promoters 26.9%, Public 73.1%.Jun '25: Promoters 26.9%, Public 73.1%.Sep '25: Promoters 26.9%, Public 73.1%.Dec '25: Promoters 26.9%, Public 73.1%.Mar '26: Promoters 26.9%, Public 73.1%.Jun '26: Promoters 26.9%, Public 73.1%.Aug '26: Promoters 30.5%, Public 69.5%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Healthy Biosciences Limited +4.97 pp 4.97% held
The same filing shows 5 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Ajooni Biotech Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Jasjot Singh | 15.98% | −0.84 pp |
| Healthy Biosciences Limited | 4.97% | +4.97 pp |
| Parmjeet Kaur | 4.30% | −0.22 pp |
| Upneet Kaur | 2.42% | −0.12 pp |
| Anantharaman Janaki | 1.81% | −0.09 pp |
| Ashmeet Kaur | 1.75% | −0.10 pp |
| Ishneet Kaur | 1.11% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹3, this stock must grow earnings at 16% every year for 7 years. Our analysis caps realistic growth at ~145%. At that growth it is worth ₹507 — upside of 14516%.
- Growth the price implies
- 15.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 94.8% a year
- net profit, FY24–FY26 · EPS 144.9%
- The gap
- -1.3 pp
- 14516% downside if it only repeats history
Learn to analyse Ajooni Biotech Limited
Guides on how to read this kind of business and the numbers that matter.